PERBANDINGAN UJI DIAGNOSTIK GENEXPERT MTB/RIF DENGAN KULTUR SENSITIVITAS ANTIBIOTIK DALAM MENDETEKSI RESISTENSI RIFAMPICIN Mycobacterium tuberculosis PADA PASIEN TB PARU DI RSUP H. ADAM MALIK MEDAN
Main Article Content
Abstract
WHO recommends GeneXpert Mycobacterium tuberculosis; Rifampicin as an initial examination for the diagnose of drug-resistant tuberculosis and drug-sensitive tuberculosis in pulmonary TB patients. The GeneXpert MTB/RIF examination is a molecular examination method with Nucleic Acid Amplification Technology (NAAT) which can diagnose TB and resistance to Rifampicin within 2 hours. The aims of this study is to determine the comparison of GeneXpert MTB/Rif Diagnostic Test with Drug Sensitivity Culture in Detecting Rifampicin M. tuberculosis resistance in TB patients at H. Adam Malik Hospital, Medan. The sample in this study was the entire population of suspected pulmonary TB at H. Adam Malik Hospital Medan who had MTB examination results. Post; rif. res. The sample size was using total sampling, namely the sampling technique where the number of samples was the same as the population, namely 128 patients in 2020. The results of the Rifampicin TCM Antibiotic Test were found that 128 people had Rifampicin Resistant results. Based on the percentage of the results of the MGIT Antibiotic Sensitivity Test, 125 people were found to have Rifampicin Resistant results and 3 people had Rifampicin Sensitive results. Based on the results, it can be seen that the sensitivity value of the TCM tool to DST MGIT culture is 97.7%. The Conclusions of these Research is the ability of the GeneXpert MTB/Rif method to detect rifampin resistance can be used as a screening tool to diagnose rifampin-resistant TB.
Downloads
Metrics
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
In submitting the manuscript to the journal, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal.
- That it is not under consideration for publication elsewhere,
- That its publication has been approved by all the author(s) and by the responsible authorities – tacitly or explicitly – of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
License and Copyright Agreement
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.